Pseudonymized patient record data as well as raw data from antibody, avidity, and live-virus neutralization measurements in patients with hematopoietic neoplasia and healthy donors.THIS DATASET IS ARCHIVED AT DANS/EASY, BUT NOT ACCESSIBLE HERE. TO VIEW A LIST OF FILES AND ACCESS THE FILES IN THIS DATASET CLICK ON THE DOI-LINK ABOV
Background: A potentially important aspect of the humoral immune response to Covid-19 is avidity, th...
Patients with indolent lymphoma undertaking recurrent or continuous B cell suppression are at risk o...
The interactions between antibodies, SARS-CoV-2 and immune cells contribute to the pathogenesis of C...
Individuals with hematologic malignancies are at increased risk for severe coronavirus disease 2019 ...
Importance: It has become common practice to offer immunocompromised patients with hematologic cance...
IMPORTANCE It has become common practice to offer immunocompromised patients with hematologic cancer...
Abstract Recent data suggest a suboptimal antibody response to COVID-19 vaccination in patients with...
It is unclear whether patients with cancer present inherently impaired responses to COVID-19 and vac...
Abstract There is currently a critical need to determine the efficacy of SARS-CoV-2 vaccination for ...
Research on COVID-19 vaccination in immune-deficient/disordered people (IDP) has primarily focused o...
Vaccination guidelines for patients treated for hematological diseases are typically conservative. G...
Patients with blood cancer continue to have a greater risk of inadequate immune responses following ...
BackgroundLong-term immunity to SARS-CoV-2 infection, including neutralizing antibodies and T cell-m...
Neutralizing antibodies against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are...
Multiple myeloma (MM) patients are at higher risk for severe COVID-19. Their mRNA vaccination respon...
Background: A potentially important aspect of the humoral immune response to Covid-19 is avidity, th...
Patients with indolent lymphoma undertaking recurrent or continuous B cell suppression are at risk o...
The interactions between antibodies, SARS-CoV-2 and immune cells contribute to the pathogenesis of C...
Individuals with hematologic malignancies are at increased risk for severe coronavirus disease 2019 ...
Importance: It has become common practice to offer immunocompromised patients with hematologic cance...
IMPORTANCE It has become common practice to offer immunocompromised patients with hematologic cancer...
Abstract Recent data suggest a suboptimal antibody response to COVID-19 vaccination in patients with...
It is unclear whether patients with cancer present inherently impaired responses to COVID-19 and vac...
Abstract There is currently a critical need to determine the efficacy of SARS-CoV-2 vaccination for ...
Research on COVID-19 vaccination in immune-deficient/disordered people (IDP) has primarily focused o...
Vaccination guidelines for patients treated for hematological diseases are typically conservative. G...
Patients with blood cancer continue to have a greater risk of inadequate immune responses following ...
BackgroundLong-term immunity to SARS-CoV-2 infection, including neutralizing antibodies and T cell-m...
Neutralizing antibodies against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are...
Multiple myeloma (MM) patients are at higher risk for severe COVID-19. Their mRNA vaccination respon...
Background: A potentially important aspect of the humoral immune response to Covid-19 is avidity, th...
Patients with indolent lymphoma undertaking recurrent or continuous B cell suppression are at risk o...
The interactions between antibodies, SARS-CoV-2 and immune cells contribute to the pathogenesis of C...